Huntington's disease: what uniQure's three-year AMT-130 gene-therapy data actually shows

After half a century without a disease-modifying treatment, Huntington's disease has had its breakthrough moment. Dutch biotech uniQure released 36-month follow-up data on its AMT-130 single-dose gene therapy: the 12 patients who received the high dose progressed roughly 75 per cent more slowly than natural-history controls on the cUHDRS, the standard composite clinical scale. STAT News's The Readout LOUD podcast called it one of the rare true breakthrough moments in the field.

Huntington's is an autosomal dominant neurodegenerative disorder caused by an expanded CAG repeat in the HTT gene. Symptoms typically emerge between 30 and 50 — choreographic involuntary movements, personality change, cognitive decline — and the disease is fatal, usually within 15 to 20 years. Until now there has been no approved disease-modifying treatment; clinical care has been entirely symptomatic.

AMT-130 is an adeno-associated virus (AAV5) vector therapy delivered directly to the brain through stereotactic surgery. The single dose carries a microRNA targeting the HTT gene's mRNA, shutting down production of the toxic mutant huntingtin protein. In uniQure's data, cerebrospinal-fluid neurofilament light chain — a biochemical marker of neuronal damage — fell by 11 per cent from baseline in the high-dose group while rising by 26 per cent in controls.

STAT senior writer Damian Garde said on the podcast: "The real value of the AMT-130 data is that you see movement in both patient-reported functional measures and biochemical markers. It is not a result resting on a single noisy endpoint." Garde said it is one of the few neurodegenerative cohorts where the treatment effect meets the FDA's clinically meaningful threshold on both clinical and biological axes.

uniQure's chief executive Matt Kapusta said the data sets the company up to file for FDA accelerated approval before the end of June. Accelerated approval allows life-threatening conditions to be treated before full Phase III data is in, on condition that a confirmatory trial follows; uniQure said its Phase 3 EXPEDITE trial is already enrolling.

Pricing has not been disclosed. The reference range for one-shot gene therapies approved so far — Casgevy for sickle-cell, Elevidys for Duchenne — has been $2-3.5 million per patient. The Huntington's prevalence is roughly 41,000 in the United States and 45,000 in Europe. The economic modelling is daunting, but a one-time payment is at least directly comparable with the lifetime cost of chronic management.

Genetic testing can identify the expanded CAG repeat in HTT decades before symptoms appear. That opens the question of presymptomatic intervention — should an approved AMT-130 be used in genetic carriers before clinical disease starts, or only after? The current data covers early symptomatic patients only; presymptomatic use would require a separate trial.

The same podcast carried a midterm report card on Robert F Kennedy Jr's six months as US Health and Human Services secretary. STAT reporters tested his confirmation pledges — banning food dyes, reassessing mRNA vaccines, redirecting NIH research — against concrete administrative actions. Some contract cancellations and advisory-board reshuffles have moved at speed; questions over CDC independence and vaccine-monitoring processes are still open.

A test case came when the FDA's vaccine advisory committee voted unanimously to recommend Moderna's mRNA flu vaccine, despite Kennedy's known scepticism. That was read as a signal that the agency's scientific process is still operating independently of any technology-specific scepticism at the top of the department. STAT reporters described that outcome as significant for the agency's room for independent action.

The AMT-130 result also matters for the wider field. mRNA-silencing technologies — antisense oligonucleotides, small interfering RNAs, CRISPR-based suppressors — are starting to open alternative paths in neurodegenerative diseases that have repeatedly defeated previous approaches. If AMT-130 is approved, it could be the cornerstone evidence for similar strategies in familial ALS, the genetic forms of Alzheimer's, and frontotemporal dementia.